Clinical Trial

22G-Adapt vs 22G-Franseen Needle Biopsy in EUS-Guided Tissue Acquisition of Solid Lesions

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The investigators conduct a prospective, multicenter, blinded, randomized controlled trial to compare the diagnostic value and safety of the 22G Adapt needle versus the 22G Franseen needle for histopathological evaluation of solid lesions.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-07; most recent amendment 2025-06-29.
Trial Details
NCT Number NCT07012694
Lead Sponsor Huazhong University of Science and Technology
Collaborators: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital of Anhui Medical University, The First People's Hospital of Yunnan, The First Affiliated Hospital of University of Science and Technology of China
Conditions Pancreatic Neoplasms, Mediastinal Neoplasms, Abdominal Neoplasm, Excluding Pancreas Neoplasm
Enrollment 576 participants
Start Date 2025-07
Primary Completion 2026-09 (estimated)
Study Completion 2026-12-10 (estimated)
Updated on ClinicalTrials.gov 2025-07-01